Rapport Therapeutics, Inc. - Common Stock (NQ:RAPP)

42.77 +2.38 (+5.89%)

Streaming Delayed Price Updated: 1:15 PM EDT, Jun 30, 2026 Add to My Watchlist

Price and Volume

Volume	308,367
Open	40.40
Bid (Size)	42.77 (100)
Ask (Size)	43.13 (200)
Prev. Close	40.39
Today's Range	40.00 - 43.76
52wk Range	11.05 - 42.27
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

May 20, 2026

From Rapport Therapeutics, Inc.

Via GlobeNewswire

Rapport Therapeutics (NASDAQ:RAPP) Beats Q1 Estimates, Guided by Strong Seizure Data and Accelerated Timelines ↗

May 07, 2026

Via Chartmill

Performance

YTD	+52.2%	+52.2%
1 Month	+15.3%	+15.3%
3 Month	+54.5%	+54.5%
6 Month	+41.4%	+41.4%
1 Year	+276.2%	+276.2%

More News

Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update

May 07, 2026

From Rapport Therapeutics, Inc.

Via GlobeNewswire

Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near ↗

April 27, 2026

Via The Motley Fool

Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting

April 21, 2026

From Rapport Therapeutics, Inc.

Via GlobeNewswire

Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting

April 01, 2026

From Rapport Therapeutics, Inc.

Via GlobeNewswire

This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗

March 16, 2026

Via The Motley Fool

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗

March 16, 2026

Via The Motley Fool

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗

March 16, 2026

Via The Motley Fool

This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter ↗

March 16, 2026

Via The Motley Fool

Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 10, 2026

From Rapport Therapeutics, Inc.

Via GlobeNewswire

Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China

March 09, 2026

From Rapport Therapeutics, Inc.

Via GlobeNewswire

Rapport Therapeutics to Participate in Upcoming Investor Conferences

February 24, 2026

From Rapport Therapeutics, Inc.

Via GlobeNewswire

Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline

January 07, 2026

From Rapport Therapeutics, Inc.

Via GlobeNewswire

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗

December 22, 2025

Via The Motley Fool

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

Via MarketMinute

Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 18, 2025

From Rapport Therapeutics, Inc.

Via GlobeNewswire

Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures

December 05, 2025

From Rapport Therapeutics, Inc.

Via GlobeNewswire

Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting

November 25, 2025

From Rapport Therapeutics, Inc.

Via GlobeNewswire

This Extreme Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

November 19, 2025

Via Benzinga

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

Via MarketMinute

Rapport Therapeutics Inc (NASDAQ:RAPP) Reports Q3 2025 Earnings Beat and Positive Phase 2a Seizure Data ↗

November 06, 2025

Via Chartmill

Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update

November 06, 2025

From Rapport Therapeutics, Inc.

Via GlobeNewswire

Rapport Therapeutics to Participate in Upcoming Investor Conferences

November 05, 2025

From Rapport Therapeutics, Inc.

Via GlobeNewswire

Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

September 11, 2025

From Rapport Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Rapport Therapeutics, Inc. - Common Stock publicly traded?

Yes, Rapport Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Rapport Therapeutics, Inc. - Common Stock trade on?

Rapport Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Rapport Therapeutics, Inc. - Common Stock?

The ticker symbol for Rapport Therapeutics, Inc. - Common Stock is RAPP on the Nasdaq Stock Market

What is the current price of Rapport Therapeutics, Inc. - Common Stock?

The current price of Rapport Therapeutics, Inc. - Common Stock is 42.77

When was Rapport Therapeutics, Inc. - Common Stock last traded?

The last trade of Rapport Therapeutics, Inc. - Common Stock was at 06/30/26 01:15 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.